User Notice: The site will be occasionally unavailable due to scheduled maintenance this weekend. Please accept our apologies for any inconvenience.

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 148.50 145.00 152.00 149.50 148.50 149.50 52,672 12:10:40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.1 -13.9 -35.9 - 84

Reneuron Share Discussion Threads

Showing 7976 to 7998 of 8300 messages
Chat Pages: Latest  320  319  318  317  316  315  314  313  312  311  310  309  Older
DateSubjectAuthorDiscuss
08/9/2020
17:24
Things are very quiet but the AGM is on the 10th and Hunt has previously stated that there will be an update on the ph2a extension trial soon. My guess is that they will announce full details of the testing including locations and schedule. I suspect they will also say in the update that they have treated the first patient in the US.
whatno
08/9/2020
10:38
Volume is super low. This price action means nothing. It was pushed down by 50% by some small retail investors who are not patient enough to wait for the new data from clinical trails. Some people probably prefer hot covid stocks...
pawelkordala
07/9/2020
18:20
Crazy that in all the mad dash for the biotech plays, this is going the wrong way! Maybe they need to add the phrase "Covid-19" to their PR campaigns! D
dennisbergkamp
07/9/2020
17:49
Really sad to see this great company going down the pan...
bonzo
28/8/2020
09:41
Thanks for a very interesting link MMM
rotors
27/8/2020
23:33
Nice presentation here. Good one on ORPH also. https://www.youtube.com/watch?v=aaguza4wO9I
malcolmmm
27/8/2020
07:23
I think people need to be patient on this one. They will probably deliver, but they just need more data.
pawelkordala
26/8/2020
09:21
Edison u/g the value of the company to £170m from £107m hxxps://www.edisongroup.com/publication/exploiting-the-potential-of-cell-therapy/27598
bg23
03/8/2020
12:38
Problem is we need to get out of this downward trend .
brianking1pin
02/8/2020
21:53
There are a number of very large pharmas trying to enhance their portfolios in optometry. For the phase2a extension study,RENE have clearly taken feedback from some of these in designing the trial efficacy signals. They have world class expertise in the.two Principal Investigators and the influence tne PIs will have with big pharma should be very significant in sealing an early deal. If the results of the extension study are at least as good as the phase 2a then this would equal or exceed results obtained for approved gene therapy products in RP. I very.much doubt they will have a problem raising additional finamce. My bet is that it will come from a US institutional investor/VC.
onceaday
02/8/2020
21:08
Need multiple Row partners to spread risk here. Hopefully some incoming partners funds to see through any future financial limitations.
hollywood6
02/8/2020
21:07
A worry for sure
hollywood6
31/7/2020
10:31
Confidence building in both partners and shareholders with each announcement. Could be well over £3 given a following wind during the next 12 months.
small crow
31/7/2020
09:42
Just a shame that the partnership deal is with a Chinese company given the current climate.
bantam175
31/7/2020
09:38
Let's hope they start the ph2a extension study soon. If indeed the company needs to raise.funds then they will be doing all they can to get the share price higher. I suspect they will release an ipdate within one.month of treating a subset of the planned 9 patients if results are "material". Possibly within the.next 90 days.
onceaday
31/7/2020
09:16
Very good level to be buying at the moment, Just wish that I was able to say that I entered below £1.30. IF only !
brianking1pin
31/7/2020
09:04
Good move this am
ayl30
28/7/2020
20:37
That appears to be the case. If you watch some of the jCyte presentations on youtube, the mode of operation is to rescue dying photoreceptors but it is not thought to result in new photoreceptors integrating into the retina. RENE has shown through experiments in pigs eyes that they do get integration after sub-retinal injection. Given that the ph2a study results were dose dependent, we could see improved efficacy due to doubling the dose to 2million cells in the ph2a extension study.
onceaday
28/7/2020
20:04
Agreed all. Jcyte do not have the cryo formulation, so have a few days rather than 6 months shelf life. Also, Reneuron believe that because of the difference in administration (the layer they go into) they (Jcyte) may not be growing new photoreceptors only providing trophic? support.
philh75
28/7/2020
19:27
Onceaday, Correct. There's plenty of room for more than one player here. And differences/advantages of each will emerge. Good time to buy IMO.
small crow
28/7/2020
17:26
If you read into the detail of yhe results, you will find it was a triple arm trial - they used a sham (no dose), low dose and high dose arm. Only the high dose arm showed meaningfull efficacy andonly a sub population showed comparable efficacy to RENE's ph2a results.. RENE will treat a further 9 patients at double dose in the ph2a extension trial. The fact that jCute had good results with the same type of hRPC cell validates RENEs work so far amd adds value. I think there will be a number of large pharmas keeping a very close eye (excuse the pun) on the extension trial. It's open label,unlike the jCyte ph2b, so they can announce tesults as they go. Biotech investment is all about timing - it can take years (decades) for value inflection - it could be that RENE's time has finally arrived.
onceaday
27/7/2020
20:48
Well that new bloke brought in to do deals sure ain't cutting it is he ?
martinfrench
27/7/2020
17:17
There are quite a few US players looking to buy into RP drugs and only two companies who are well advanced in that field and happy to outlicence their drugs. I think jCyte success will only increase interest in a deal with Reneuron and the regulators doesn't seem to have a problem with only 10-20 patients in their study.
pawelkordala
Chat Pages: Latest  320  319  318  317  316  315  314  313  312  311  310  309  Older
ADVFN Advertorial
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210507 14:33:09